Exclusive press program selection highlights growing patient access to one-time treatments for sickle cell disease and transfusion-dependent thalassemia.
Somerville, Massachusetts, 4 December 2025 – Genetix Biotherapeutics Inc. has been selected to participate in the American Society of Hematology’s (ASH) exclusive press program ahead of the 67th ASH Annual Meeting in Orlando, Florida. The company’s featured abstract, “Accelerating access to gene therapy: Lessons from commercial implementation in sickle cell disease and transfusion-dependent thalassemia,” was chosen as one of the most impactful datasets submitted to ASH this year.
In simple terms, Genetix is being recognized for showing how real patients are gaining faster access to life-changing gene therapy treatments designed to offer a durable, one-time solution for serious blood disorders.
Dr. Joanne Lager, Chief Medical Officer at Genetix, said the recognition reflects the importance of their findings. She highlighted that the data offer the first real-world look at how gene therapies like ZYNTEGLO and LYFGENIA are being adopted in the commercial market. “We’re seeing strong demand and real scalability,” she noted, adding that Genetix has accelerated access for sickle cell patients by improving logistics, shortening wait times, and expanding treatment centers.
Since the FDA approved ZYNTEGLO in August 2022 and LYFGENIA in December 2023, nearly 370 patients have begun the treatment process, with 115 already treated as of mid-November 2025. Genetix’s revamped commercial strategy, built from lessons learned during the first product launch, has helped more sickle cell patients reach treatment sooner.
Despite this progress, Genetix emphasized that thousands of eligible patients still have not yet received gene therapy. The company says it remains committed to investing in U.S. infrastructure and expanding access so more people can benefit from these advanced therapies.